Physiologically‐based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women
- 22 July 2015
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 80 (5) , 1031-1041
Abstract
Aim: Physiological changes during pregnancy can affect drug disposition. Anticipating these changes will help to maximize drug efficacy and safety in pregnant women. Our objective was to determine if physiologically‐based pharmacokinetics (PBPK) can accurately predict changes in the disposition of renally excreted antiretroviral drugs during pregnancy.Methods: Whole body PBPK models were developed for three renally excreted antiretroviral drugs, tenofovir (TFV), emtricitabine (FTC) and lamivudine (3TC). To assess the impact of pregnancy on PK, time‐varying pregnancy‐related physiological parameters available within the p‐PBPK Simcyp® software package were used. Renal clearance during pregnancy followed glomerular filtration changes with or without alterations in secretion. PK profiles were simulated and compared with observed data, i.e. area under the curves (AUC), peak plasma concentrations (Cmax) and oral clearances (CL/F).Results: PBPK models successfully predicted TFV, FTC and 3TC disposition for non‐pregnant and pregnant populations. Both renal secretion and filtration changed during pregnancy. Changes in renal clearance secretion were related to changes in renal plasma flow. The maximum clearance increases were approximately 30% (TFV 33%, FTC 31%, 3TC 29%).Conclusions: Pregnancy PBPK models are useful tools to quantify a priori the drug exposure changes during pregnancy for renally excreted drugs. These models can be applied to evaluate alternative dosing regimens to optimize drug therapy during pregnancy.Keywords
Funding Information
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
This publication has 40 references indexed in Scilit:
- A Physiologically Based Pharmacokinetic Model to Predict Disposition of CYP2D6 and CYP1A2 Metabolized Drugs in Pregnant WomenDrug Metabolism and Disposition, 2013
- The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant womenAIDS, 2013
- Drug Metabolism and Transport During Pregnancy: How Does Drug Disposition Change during Pregnancy and What Are the Mechanisms that Cause Such Changes?Drug Metabolism and Disposition, 2013
- A pregnancy physiologically based pharmacokinetic (p‐PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4British Journal of Clinical Pharmacology, 2012
- A PBPK Model to Predict Disposition of CYP3A‐Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A InductionCPT: Pharmacometrics & Systems Pharmacology, 2012
- Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal PregnancyClinical Pharmacokinetics, 2012
- Antiretroviral Tissue Kinetics: In Vivo Imaging Using Positron Emission TomographyAntimicrobial Agents and Chemotherapy, 2009
- Population Pharmacokinetics of Tenofovir in Human Immunodeficiency Virus-Infected Patients Taking Highly Active Antiretroviral TherapyAntimicrobial Agents and Chemotherapy, 2005
- Application of a Physiologically Based Pharmacokinetic Model for Isopropanol in the Derivation of a Reference Dose and Reference ConcentrationRegulatory Toxicology and Pharmacology, 2002
- A computer model and program for xenobiotic disposition during pregnancyComputer Methods and Programs in Biomedicine, 1997